Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy

NCT01308567 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01308567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01308567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
May 5, 2011
Completion date
May 31, 2018
Enrollment
1,168 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer